Dörner, Thomas
van Vollenhoven, Ronald F.
Doria, Andrea
Jia, Bochao
Ross Terres, Jorge A.
Silk, Maria E.
de Bono, Stephanie
Fischer, Peter
Wallace, Daniel J.
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 22 December 2021
Accepted: 26 April 2022
First Online: 16 May 2022
Declarations
:
: All studies were approved by the applicable ethical review boards at each participating study site and were conducted in accordance with the principles expressed in the Declaration of Helsinki of 1964 and its subsequent amendments. Written, informed consent was obtained from each patient at study entry before any study procedures took place.
: Not applicable.
: TD has received grant support from Chugai, Janssen, Novartis, and Sanofi. He has received consultancy support from AbbVie, Celgene, Eli Lilly and Company, Janssen, Novartis, Roche, Samsung, and UCB, and speaker bureau fees from Eli Lilly and Company and Roche. RFV has received consultancy support from AbbVie, Biotest, BMS, Celgene, Crescendo, Eli Lilly and Company, GSK, Janssen, Merck, Novartis, Pfizer, Roche, UCB, and Vertex. AD has received consultancy support from GSK, Eli Lilly and Company, and Celgene and has speaker bureau fees from GSK, Pfizer, Roche, and Janssen. DJW has received consulting support from Amgen, Eli Lilly and Company, EMD Merck Serono, and Pfizer. BJ, JRT, MS, SB, and PF are employees and shareholders of Eli Lilly and Company.